Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.63 |
| ▸ | EGFR | P00533 | 7/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | BLK | P51451 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 4/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | JAK1 | P23458 | 2/20 | 0.57 |
| ▸ | TYK2 | P29597 | 1/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | TTK | P33981 | 1/20 | 0.56 |
| ▸ | ITK | Q08881 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17071732 | 0.93 | BTK (0.67) | BTKEGFRFLT3BLKJAK3 | |
| SCHEMBL17071523 | 0.93 | BTK (0.72) | BTKEGFRFLT3BLKJAK3 | |
| SCHEMBL17071355 | 0.92 | BTK (0.64) | BTKEGFRFLT3BLKJAK3 | |
| SCHEMBL17071491 | 0.91 | EGFR (0.61) | BTKEGFRFLT3BLKJAK3 | |
| SCHEMBL17071710 | 0.91 | BTK (0.61) | BTKEGFRFLT3BLKJAK3 | |
| SCHEMBL19645887 | 0.91 | BTK (0.58) | BTKEGFRFLT3BLKJAK3 | |
| SCHEMBL17071694 | 0.91 | BTK (0.58) | BTKEGFRFLT3BLKJAK3 | |
| SCHEMBL17071409 | 0.91 | BTK (0.58) | BTKEGFRFLT3BLKJAK3 | |
| SCHEMBL17071698 | 0.91 | BTK (0.62) | BTKEGFRFLT3BLKJAK3 | |
| SCHEMBL17071722 | 0.90 | BTK (0.57) | BTKEGFRFLT3BLKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2018-05-17 | — | — | US | disclosed |
| US-9828376-B2 | Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150252048-A1 | SUBSTITUTED N-(3-PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252048-A1 | SUBSTITUTED N-(3-PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885EGFR 294/4885FLT3 10/4885 |
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885EGFR 323/4885FLT3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.